ConductScience.org, home

Paper36966788

Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis.

Winters N and 14 others. Lancet Respir Med, 2023. Cited by 32 papers, by iCite.

Cite this record

ConductScience Library. Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. Papers, record 36966788. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36966788

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis.
PubMed
Journal
Lancet Respir Med
PubMed
Year
2023
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Network Meta-Analysis
PubMed
Citations, by iCite
32
iCite
Relative citation ratio, by iCite
4.07
iCite
Revised in PubMed
2026-01-27
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Winters NNicholas
2Belknap RRobert
3Benedetti AAndrea
4Borisov AAndrey
5Campbell JRJonathon R
6Chaisson RERichard E
7Chan PCPei-Chun
8Martinson NNeil
9Nahid PPayam
10Scott NANigel A
11Sizemore EErin
12Sterling TRTimothy R
13Villarino MEM Elsa
14Wang JYJann-Yuan
15Menzies DDick

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Latent TuberculosisMajor topic
TuberculosisMajor topic
Humans
Rifampin
Isoniazid
Antitubercular Agents
Drug Therapy, Combination

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
CC999999Intramural CDC HHSUnited StatesPubMed

Source PubMed

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in36966789Shorter regimens for tuberculosis preventive treatment: piecing together the global implementation jigsaw.https://conductscience.org/library/papers/36966789

Source PubMed

Download CSV of comments and corrections

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125904367
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Clin Infect Dis2015https://conductscience.org/library/papers/25904367PubMed
225814376WHO's new end TB strategy.Lancet2015https://conductscience.org/library/papers/25814376PubMed
31731596
A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council.
Am Rev Respir Dis1992https://conductscience.org/library/papers/1731596PubMed
417712755
The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study.
Clin Infect Dis2007https://conductscience.org/library/papers/17712755PubMed
529114781Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.Ann Intern Med2017https://conductscience.org/library/papers/29114781PubMed
627116943A scoping review of indirect comparison methods and applications using individual patient data.BMC Med Res Methodol2016https://conductscience.org/library/papers/27116943PubMed
729580819Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies.Lancet Infect Dis2018https://conductscience.org/library/papers/29580819PubMed
817504683[Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients].Enferm Infecc Microbiol Clin2007https://conductscience.org/library/papers/17504683PubMed
919017587Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.Ann Intern Med2008https://conductscience.org/library/papers/19017587PubMed
109295239A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.N Engl J Med1997https://conductscience.org/library/papers/9295239PubMed
1125519784Accelerating progress towards tuberculosis elimination: the need for combination treatment and prevention.Int J Tuberc Lung Dis2015https://conductscience.org/library/papers/25519784PubMed
1231462531RoB 2: a revised tool for assessing risk of bias in randomised trials.BMJ2019https://conductscience.org/library/papers/31462531PubMed
1325580725Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.JAMA Pediatr2015https://conductscience.org/library/papers/25580725PubMed
1426951571Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada.Clin Infect Dis2016https://conductscience.org/library/papers/26951571PubMed
1529910114Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis.Am J Prev Med2018https://conductscience.org/library/papers/29910114PubMed
1618926033Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada.Int J Tuberc Lung Dis2008https://conductscience.org/library/papers/18926033PubMed
1711684933Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults.AIDS2001https://conductscience.org/library/papers/11684933PubMed
1830067928Safety and Side Effects of Rifampin versus Isoniazid in Children.N Engl J Med2018https://conductscience.org/library/papers/30067928PubMed
1922419641Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence.J Correct Health Care2012https://conductscience.org/library/papers/22419641PubMed
2030067931Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults.N Engl J Med2018https://conductscience.org/library/papers/30067931PubMed

See all 28 referencesDownload CSV of references

Cited by26

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.

PMIDTitleJournalYearIn PapersSource
42942179Integrated Structural, Physicochemical, Pharmacokinetic and Pharmacodynamic Evaluation of Substituted Phenylcarbonyloxypiperazinopropanols as Antimycobacterial Agents.Life (Basel)2026https://conductscience.org/library/papers/42942179PubMed
42872138
High Initiation but Suboptimal Completion of Tuberculosis-Preventive Treatment Among People Living With HIV on Antiretroviral Therapy, Persistent Tuberculosis Incidence, and Programmatic Implications: Findings From a 2-Year Multicountry Cohort Study.
Open Forum Infect Dis2026https://conductscience.org/library/papers/42872138PubMed
42841008Tuberculosis Incidence and Predictors Among People Living With HIV After Isoniazid-Rifapentine (3HP) Preventive Therapy in Ethiopia: A Retrospective Cohort Study.J Trop Med2026https://conductscience.org/library/papers/42841008PubMed
42758766
Scaling-up tuberculosis preventive therapy to HIV-negative contacts of bacteriologically confirmed TB cases aged 5 years and above - Lessons from a tuberculosis preventive therapy surge activity in Zambia.
PLOS Glob Public Health2026https://conductscience.org/library/papers/42758766PubMed
42373911Breaking barriers: Implementation of a tuberculosis preventive treatment protocol among newly eligible populations with promising results.Eur J Clin Microbiol Infect Dis2026https://conductscience.org/library/papers/42373911PubMed
42369968Infectious Disease Provider Perspectives on Shorter Tuberculosis Treatment Regimens.Open Forum Infect Dis2026https://conductscience.org/library/papers/42369968PubMed
42136397Three Months of Weekly Rifapentine and Isoniazid Versus Four Months of Daily Rifampicin for Tuberculosis Infection: A Randomized Controlled Trial.Clin Infect Dis2026https://conductscience.org/library/papers/42136397PubMed
42116841Tuberculosis Prevention in Pregnant Women Living with HIV: A Review of the Current Management Strategies and Guidance.Infect Drug Resist2026https://conductscience.org/library/papers/42116841PubMed
42088243Acceptance, completion, and safety of the 3HR regimen for latent tuberculosis infection: a prospective cohort study in China.Front Public Health2026https://conductscience.org/library/papers/42088243PubMed
42077650
Efficacy, safety, and completion of modified short-course rifapentine and isoniazid for latent tuberculosis infection in patients with high-risk rheumatic disease: a multicentre, open-label, randomized, non-inferiority trial.
EClinicalMedicine2026https://conductscience.org/library/papers/42077650PubMed
41592909The implementation of tuberculosis preventive therapy in HIV care clinics in Africa, Asia and Latin America: a multiregional site survey.BMJ Glob Health2026https://conductscience.org/library/papers/41592909PubMed
41544145Identifying missed opportunities in tuberculosis preventive treatment care cascade: Analysis of programme data from Maharashtra, India.PLOS Glob Public Health2026https://conductscience.org/library/papers/41544145PubMed
41248394Functional Outcomes, Lung health and Livelihood Outcomes among people With Tuberculosis (FOLLOW-TB): study protocol for a multicentre, prospective cohort study in Canada.BMJ Open2025https://conductscience.org/library/papers/41248394PubMed
41191713Treatment completion rates and adverse effects of three months of once-weekly isoniazid plus rifapentine for latent tuberculosis infection.J Bras Pneumol2025https://conductscience.org/library/papers/41191713PubMed
41089227Risks and consequences of TB and its prevention in cost-utility analyses among immigrants: a systematic review.IJTLD Open2025https://conductscience.org/library/papers/41089227PubMed
41059819[The effect of the 3HP regimen on the completion of preventive tuberculosis treatment in people living with HIV: a retrospective cohort in Brazil].Cad Saude Publica2025https://conductscience.org/library/papers/41059819PubMed
40980570Costs of 4 Months of Rifampin Versus 2 Months of Double-dose Rifampin for Tuberculosis Infection: Post-Hoc Analysis of a Phase 2b Randomized Trial.Open Forum Infect Dis2025https://conductscience.org/library/papers/40980570PubMed
40768149Integrating Early Tuberculosis States Into Contact Management in Peru.JAMA Netw Open2025https://conductscience.org/library/papers/40768149PubMed
40326358Efficacy and safety of a novel short course rifapentine and isoniazid regimen for the preventive treatment of tuberculosis in Chinese silicosis patients: a pilot study (SCRIPT-TB).Emerg Microbes Infect2025https://conductscience.org/library/papers/40326358PubMed
40262275Prevalence and treatment outcomes of latent tuberculosis infection among older patients with chronic obstructive pulmonary disease in an area with intermediate tuberculosis burden.Emerg Microbes Infect2025https://conductscience.org/library/papers/40262275PubMed

See all 26 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36966788

GET https://conductscience.org/api/papers/v1/36966788/references?page=2